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Background: We have previously shown that human mesenchymal stem cells (hMSCs) 
can reduce toxin-induced neurodegeneration in a well characterized rodent model of 
  Parkinson’s   disease. However, the precise mechanisms, optimal cell concentration required 
for   neuroprotection, and detailed cell tracking need to be defined. We exploited a near-infrared 
imaging platform to perform noninvasive tracing following transplantation of tagged hMSCs 
in live parkinsonian rats.
Methods: hMSCs were labeled both with a membrane intercalating dye, emitting in the 
  near-infrared 815 nm spectrum, and the nuclear counterstain, Hoechst 33258. Effects of near-
infrared dye on cell metabolism and proliferation were extensively evaluated in vitro. Tagged 
hMSCs were then administered to parkinsonian rats bearing a 6-hydroxydopamine-  induced 
lesion of the nigrostriatal pathway, via two alternative routes, ie, intrastriatal or   intranasal, and 
the cells were tracked in vivo and ex vivo using near-infrared technology.
Results: In vitro, NIR815 staining was stable in long-term hMSC cultures and did not interfere 
with cell metabolism or proliferation. A significant near-infrared signal was detectable in vivo, 
confined around the injection site for up to 14 days after intrastriatal transplantation. Conversely, 
following intranasal delivery, a strong near-infrared signal was immediately visible, but rapidly 
faded and was completely lost within 1 hour. After sacrifice, imaging data were confirmed 
by presence/absence of the Hoechst signal ex vivo in coronal brain sections. Semiquantitative 
analysis and precise localization of transplanted hMSCs were further performed ex vivo using 
near-infrared imaging.
Conclusion: Near-infrared technology allowed longitudinal detection of fluorescent-tagged 
cells in living animals giving immediate information on how different delivery routes affect cell 
distribution in the brain. Near-infrared imaging represents a valuable tool to evaluate multiple 
outcomes of transplanted cells, including their survival, localization, and migration over time 
within the host brain. This procedure considerably reduces the number of animal experiments 
needed, as well as interindividual variability, and may favor the development of efficient 
  therapeutic strategies promptly applicable to patients.
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Introduction
In the past 30 years, translation of the outstanding potential of stem cells from bench 
top to clinical trials in humans has represented a major objective for the scientific 
c  ommunity. The therapeutic use of stem cells, in particular, has emerged as a   promising 
branch of regenerative medicine for treating many aggressive and/or incurable   diseases 
in humans, such as neurodegenerative disorders.1 In particular, Parkinson’s disease has 
been one of the first neurodegenerative diseases considered eligible for cellular therapy.2 
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  Parkinson’s disease affects 1%–2% of individuals over 
60 years and is mainly characterized by the progressive loss 
of a well defined population of central dopaminergic cells in 
the substantia nigra pars compacta. The potential efficacy of 
stem cells for replacement of lost neurons or as a neurotrophic 
support for spared neurons within the nigrostriatal compart-
ment has been demonstrated in preclinical models of the 
disease. Conversely, inconclusive results have been reported 
in the few open-label studies conducted so far in patients. 
Thus, considerable   progress lies ahead to reach substantial 
and detectable therapeutic effects.3 Many regulatory pathways 
and environmental   factors may govern stem cell   behavior 
  following transplantation in patients with Parkinson’s   disease.4 
The development of   effective cell-based therapies to treat 
neurodegeneration therefore requires an extensive compre-
hension of the progressive environmental cues and reciprocal 
interactions between the host and donor cells.
Human mesenchymal stem cells (hMSCs) are   promising 
candidates for rapid clinical application of stem cell therapy 
in patients with Parkinson’s disease because of their simple 
derivation from bone marrow aspirates and ease of in vitro 
expansion,5 absence of tumorigenic potential,6 and possible 
autologous derivation, avoiding major ethical and immuno-
logical problems linked to other cell types. We have recently 
shown that in rats bearing a 6-hydroxydopamine (6-OHDA)-
induced lesion of the nigrostriatal pathway, a well character-
ized Parkinson’s disease-like rodent model,7,8 intrastriatal 
transplantation of naïve hMSCs reduced ongoing neuronal 
loss in the substantia nigra pars compacta and associated 
behavioral alterations.9 Grafted cells also positively and dose-
dependently influenced endogenous neurogenesis, sustaining 
the commitment of neural progenitors towards neurons.10
Near-infrared light imaging offers new opportunities 
as a sensitive and noninvasive detection technique for 
diagnostics. This technology holds enormous potential for 
a wide variety of in vivo applications and is being increas-
ingly used in small animal research. Use of the near-infrared 
wavelength for imaging allows deep penetration into tissues 
with minimal background and high optical contrast.11,12 This 
simple technology enables live determination and imaging 
of biological targets without the need for exhaustive tissue 
sampling.13 In humans, the use of noninvasive near-infrared 
imaging has already been proposed as a routine diagnostic 
tool in stroke,14 and is currently employed as a valuable 
bedside device for in vivo targeting of cancer and other 
tissue abnormalities.15 In the present study, we evaluated 
the feasibility of using near-infrared imaging to perform a 
longitudinal study and track in vivo the fate of hMSCs tagged 
with a near-infrared-excitable membrane linker in 6-OHDA 
parkinsonian-like rats. Outcomes of two alternative delivery 
routes, ie, intrastriatal or intranasal administration, were 
compared to clarify the progression of engraftment mecha-
nisms by near-infrared imaging. This technology allowed 
rapid and efficient   real-time detection of labeled cells in vivo 
in anesthetized animals. It also permitted easy follow-up 
of transplanted cells over time and within the same cohort of 
animals, thereby considerably reducing both the number of 
rats required and time-consuming analyses of serial tissue 
samples. Our data show that near-infrared technology is a 
simple and readily available technology that assures rapid 
semiquantitative analysis and immediate traceability of 
tagged hMSCs following transplantation both in vivo in 
anesthetized animals and ex vivo in tissue sections.
Materials and methods
human mesenchymal stem cells
Commercial  hMSCs  were  purchased  (Cambrex, 
Walkersville, MD) and adherent cells were grown until 
confluence in the appropriate medium (MSCBM, Cambrex) 
according to the manufacturer’s instructions. All in vitro 
and in vivo experiments were conducted with cells between 
passages 2–6 in vitro. hMSCs were subjected to karyotypic 
analysis to confirm the absence of any heterochromatin aber-
rations, as described elsewhere.9
NIR815 labeling of cultured hMSCs
Cells were labeled using the CellVue® NIR815 Midi Kit for 
membrane labeling (Polyscience, Warrington, PA)   following 
the manufacturer’s instructions. This procedure allows 
stable incorporation of a NIR815 dye into lipid regions of 
the cell membrane that can be readily detected using the 
Odyssey® scanner and imaging system (Li-Cor® Biosci-
ences, Lincoln, NE).
Briefly, 1 × 106 cells were washed twice with phosphate-
buffered saline (Sigma-Aldrich, St Louis, MO), in the 
absence of Ca2+ and Mg2+, and collected. Pellets were resus-
pended in 50 µL of diluent C with gentle mixing, and the dye 
solution was added to the cell suspension and incubated for 
5 minutes at room temperature. The reaction was blocked by 
adding fetal bovine serum (Sigma-Aldrich, 1:1 v/v), and the 
cells were washed to eliminate unbound dye and plated inside 
a T75 cm2 flask in MSCBM medium. The cells were also 
labeled with fluorescent dye, ie, bisbenzimide-Hoechst 33258 
(1 ng/mL; Molecular Probes, Invitrogen, Carlsbad, CA) to 
allow their immunofluorescent detection on brain slices using 
conventional microscopy.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
436
Bossolasco et alInternational Journal of Nanomedicine 2012:7
Cell survival and proliferation
Cell proliferation was tested on unlabeled hMSCs and 
NIR815 hMSCs over six passages in vitro. Cells were plated 
in a T75 cm2 flask (5 × 105 cells/flask at T0). In confluent 
  cultures (6–7 days in vitro), cells were counted by Trypan 
blue exclusion and expanded in T75 cm2 flasks. Values 
represent the total number of NIR815-unlabeled or NIR815-
labeled hMSCs counted at each passage.
Cell survival was evaluated at the same time points by a 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- 
(4-sulfophenyl)-2H-tetrazolium (MTS) assay (CellTiter 96® 
AQueous Assay, Promega, Madison, WI) following the 
manufacturer’s instructions, starting 1 day after the near-
infrared labeling procedure. Briefly, NIR815 hMSCs were 
plated in 96-well plate (5 × 104 cells/well) and maintained at 
37°C. After 1 hour, MTS solution (20 µL/well) was added to 
the cells and incubation was continued at 37°C for another 
hour. Supernatants were then collected, centrifuged at 2000 g 
for 5 minutes, and optical density was read at 490 nm using 
a microplate reader (El × 800, Bio-Tek Instruments Inc, 
Winooski, VT). Each sample was performed in triplicate 
and at least three separate experiments were conducted for 
both methodologies.
Maintenance of NIR815 dye  
in hMSCs over time
hMSCs (P3) were labeled as described above, plated in 
T75 cm2 flasks (5 × 105 cells/flask) and maintained in 
culture. At different time points after labeling (24 hours, 
or 14 or 28 days in vitro) NIR815 hMSCs were collected, 
counted, and serial dilutions (300, 150, 80, 40, 20, 10, 5, 
and 2 × 103 cells) were plated on coverglasses. Cells were 
fixed with 4% paraformaldehyde (20 minutes at room 
temperature, Sigma-Aldrich) and mounted with Fluorsave 
(Calbiochem, La Jolla, CA). Semiquantitative evaluation of 
NIR815   intensity in cells was performed using the Odyssey® 
imager (see below). Unlabeled hMSCs (3 × 105 cells/cover-
glass) were used as a negative control.
Transfer of NIR815 and hoechst  
33258 dyes
hMSCs were double-labeled with NIR815 dye and Hoechst 
33258, as described above (NIR815 labeling of cultured 
hMSCs) and plated in T75 cm2 flasks (5 × 105 cells/flask). 
Conditioned media were collected at different time points 
after labeling (24 and 72 hours) and cell debris were elimi-
nated by a brief centrifugation step (1200 g for 10 minutes). 
  Resulting conditioned media (CM24 and CM72) were 
directly added to 5 × 104 unlabeled hMSCs plated on 
  coverglasses and incubation proceeded for a further 24 hours. 
Cells were then washed, fixed with 4% paraformaldehyde, 
and processed for immunocytochemical staining using an 
anti-CD90 primary antibody (BD Pharmingen, Franklin 
Lakes, NJ), a membrane marker expressed by hMSCs, 
as described   elsewhere.16 IRDye® 700 and AlexaFluor594 
secondary antibodies (M-Medical, Milano, Italy, dilution 
1:10,000) were used, respectively, for near-infrared and 
microscopic evaluation of dye l  eakage. At the end of the stain-
ing   procedure,   coverglasses were either placed in a 24-well 
plate and covered with phosphate-buffered saline (near-
infrared evaluation) or mounted with Fluorsave (microscopic 
evaluation). Presence or absence of NIR815 was assessed 
using the Odyssey® imager (for   near-infrared 700 and near-
infrared 800 scan intensity: 8 and 3, respectively; resolution 
21 µm; focus 3 mm). Unlabeled hMSCs (CTR-) and NIR815/ 
Hoechst+ hMSCs (CTR+; both 5 × 104 cells/coverglass) were 
used as negative and positive controls, respectively. Similarly, 
the presence of or the absence of  Hoechst staining was 
evaluated using a fluorescent microscope (  ImageM2, Zeiss, 
Oberkochen, Germany).
In vitro near-infrared imaging
For relative quantification of signal intensity, near-infrared 
images were obtained using the Odyssey® imager. Briefly, cov-
erglasses were placed on the surface of the imager and high-
resolution scans were performed as   follows: near-infrared 700 
and near-infrared 800 scan intensity 3, resolution 21 µm, and 
focus 1 mm. For quantitative evaluation, a region of interest 
was traced around the cells, and near-infrared 700 signal 
intensity values were recorded using Odyssey® software.
Flow cytometry
FITC Annexin V in conjunction with propidium iodide 
were used to allow the identification of apoptotic, dead, and 
damaged cells. Briefly, NIR815 hMSCs were harvested, 
resuspended in 1 × binding buffer, in the presence of FITC 
Annexin V and propidium iodide (both from BD Pharmin-
gen), and incubated for 15 minutes in the dark at room 
temperature. Cells were then washed once, acquired by a 
flow cytometer (FACSCanto, II Becton Dickinson, Franklin 
Lakes, NJ) and analyzed using Diva software within 1 hour. 
Unlabeled hMSCs were used as control.
Animals
Male Sprague-Dawley rats (Charles River, Calco, LC, Italy), 
weighing 200–250 g at the beginning of the experiment, 
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were housed two per cage, at 20°C–22°C on a 12-hour 
light-dark cycle, with food and water ad libitum. Animals 
were left in the housing facilities for at least 1 week before 
the beginning of the experiments. In compliance with our 
national law, no specific ID for permission is required. 
All procedures were in accordance with the European 
Communities Council   Directive of 24 November 1986 
(86/609/EEC) and were approved by the local animal care 
committee.
Lesion surgery
Animals were anesthetized with sodium thiopental (50 mg/kg, 
Hospira, Italy), placed on a stereotaxic frame, and received 
an intrastriatal injection of 6-OHDA (20 µg/3 µL in saline 
containing 0.02% ascorbic acid; Sigma-Aldrich) into the right 
striatum at the following coordinates (mm) relative to bregma 
and the dural surface: anterior-posterior 1.0, medial-lateral 
3.0, dorsal-ventral 5.0.17 The animals were then randomly 
assigned to two subgroups for intrastriatal or intranasal 
infusion of NIR815 hMSCs.
Intrastriatal transplantation
Five days after 6-OHDA injection, a subgroup of   animals was 
anesthetized (50 mg/kg thiopental, Hospira) and underwent a 
second surgical session (  Figure 1A) in which the rats received 
an injection of NIR815 hMSCs (1.8 × 105 cells/4 µL) or 
vehicle   (phosphate-buffered saline) along two tracts in the 
ipsilateral striatum (anterior-posterior 1.8 mm, medial-
lateral 3.0 mm, dorsal-ventral 5.0 mm, and anterior-posterior 
0.2 mm, medial-lateral 3.0 mm, dorsal-ventral 5.0 mm with 
respect to bregma and dura).17
All intracerebral infusions were performed at 0.5 µL/  minute, 
using a 10 µL Hamilton syringe with a 26-gauge needle. After 
injection, the needle was left in place for 10 minutes to allow 
complete diffusion of the medium, and wounds were clipped.
To avoid possible rejection of the xenotransplant and to 
mimic standard clinical procedures in humans, all animals 
received a daily injection of cyclosporine A 10 mg/kg that 
was started 2 days before the transplantation procedure. We 
have previously demonstrated that this treatment per se has 
no influence on either the 6-OHDA-induced neurodegenera-
tive process or transplanted human cells.9
One (T1) or 14 (T14) days after cell transplantation, the 
rats were anesthetized, placed on the surface of an   Odyssey® 
imager assembled with the MousePOD Accessory (LI-
COR   Biosciences), and in vivo imaging was performed 
(see below).
Intranasal transplantation
Five days after 6-OHDA lesion, a subgroup of animals 
was anesthetized and received intranasal administration of 
NIR815 hMSCs (Figure 1B). Briefly, animals were placed 
supine on a stereotaxic frame and a cannula (32-gauge cath-
eter system; Braintree Scientific Inc, Braintree, MA) was 
placed in the left nostril so that its tip reached the olfactory 
epithelium that lies between the nostril cavity and the olfac-
tory bulb (15 mm deep). Hyaluronidase (Sigma-Aldrich), 
which has been suggested to loosen barrier function in 
A
6-OHDA
6-OHDA
NIR815-hMSCs
or PBS  (IS)
(IN)
NIR815-hMSCs
Sacrifice
Sacrifice
In vivo imaging
T1 T−5
(IS)
Days
T14
6 hours T0
Days 10 minutes intervals
In vivo imaging
T−5
T0
(IS)
In vivo imaging In vivo imaging
B
Figure 1 Schematic representation of the experimental paradigms. (A) Intrastriatal transplantation of NIR815 human mesenchymal stem cells in 6-OhDA-lesioned animals. 
(B) Intranasal infusion of NIR815 human mesenchymal stem cells in 6-OhDA-lesioned animals.
Note: See Materials and Methods section for detailed description.
Abbreviations: 6-OhDA, 6-hydroxydopamine; IS, intrastriatal; IN, intranasal; PBS, phosphate-buffered saline; hMSCs, human mesenchymal stem cells.
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the nasopharyngeal mucosa,18 was resuspended in phosphate-
buffered saline and 100 U was applied in the nostril 30 min-
utes prior to the application of the cells. NIR815 hMSCs 
(2 × 106 cells/4 µL) were administered at 0.5 µL/minute. 
Following injection, the cannula was left in place to avoid 
reflux of the cells outside of the nasal cavity. Animals were 
placed on the Odyssey® imager mounted with the Mouse-
POD® accessory, and near-infrared images were taken, as 
described below, every 10 minutes over a 1-hour period and 
again 6 hours after intranasal administration of the cells (see 
experimental procedure, Figure 1B).
In vivo near-infrared imaging
The snout or head of the animal was accurately shaved to 
reduce near-infrared background due to hair, and animals 
were maintained under sedation during all in vivo imaging 
procedures. Briefly, anesthetized animals were placed, in 
a supine position, on the Odyssey® Imager mounted with 
the MousePOD accessory so that the snout or head lay flat 
on the scanner surface; constant temperature of 37°C was 
maintained in the chamber and in vivo images were taken at 
800 nm (scan intensity 7, resolution 84 µm, focus 4.0 mm). 
Signal intensities were displayed in pseudocolor scale using 
the dedicated Odyssey® software. Semiquantitative evalua-
tion of the near-infrared signal was performed on the scanned 
images of the transplanted animals using the   Odyssey® 
software. A region of interest was drawn around the green 
near-infrared signal and near-infrared signal intensity values 
were recorded.
Sacrifice and immunohistochemistry
At the end of the experimental procedures, the animals 
were sacrificed, and the brains were removed immediately 
and conserved at −80°C. Serial coronal sections (25 µm) 
were cut throughout the striatum using a cryostat (Jung CM 
Leica, Wetzlar, Germany), picked up on poly-lysine-coated 
slides (Thermo Scientific, Waltham, MA), dried at room 
temperature, protected from light, for 1 hour and scanned 
(see below).
Immunohistochemical staining for tyrosine hydroxylase, 
the rate-limiting enzyme for dopamine synthesis, was carried 
out on every fourth section, as described elsewhere,19 using a 
specific primary antibody (MAB318, Chemicon, Millipore, 
Billerica, MA, dilution 1:2,000). An IRDye®700CW goat 
antimouse secondary antibody (M-Medical, Milano, Italy; 
dilution 1:10,000) was used for detection. Slides were dried 
for one hour in the dark, mounted using Prolong (Invitrogen), 
and scanned 1 day later (see below).
Ex vivo near-infrared imaging of brain 
coronal sections
Dried sections were scanned immediately after sectioning 
and prior to any immunohistochemical staining to allow high 
throughput detection of the transplanted cells. Briefly, slides 
were placed on the Odyssey® imager and rapid low-resolution 
scan was performed as follows: resolution 169 µm and quality 
low focus 1 mm. Channel intensities were set to 3 for 800 nm 
to visualize tagged hMSCs and 7 for 700 nm. The latter allows 
detection of nonspecific background signals from the sample 
and permits gross localization of the transplanted cells within 
the cerebral tissue.
Following tyrosine hydroxylase immunohistochem-
istry, the slides were placed, one at a time, on the 
Odyssey® imager and high resolution scan was performed 
as follows: resolution 21 µm, quality high, and focus 
1 mm. Intensity was set to 3 for both the channels (700 
and 800 nm).
Three-dimensional reconstruction  
of transplanted striata
Images of brain sections containing transplanted NIR815 
hMSCs were imported into the Neurolucida software 
  (Microbrightfield, Williston, VT). Tracing of the brain 
  outline, the left (intact) and right (transplanted) striata, as 
well as the area containing NIR815 hMSCs was performed 
on every fourth section (intersectional distance 100 µm), 
and three-dimensional brain volumes were reconstructed.
Statistical analysis
All data are expressed as the mean ± standard deviation. 
Data were compared by analysis of variance followed by 
Dunnett’s post hoc test as appropriate. Values of P , 0.05 
were considered to be statistically significant.
Results
Effect of NIR815 labeling on hMSCs
Apoptosis and cell death were evaluated by flow   cytometry 
on NIR815 hMSCs immediately and 20 hours after 
  staining using Annexin V (that binds to phospholipid 
phosphatidylserine in the cell membrane in the earlier stages 
of apoptosis) and propidium iodide (indicative of cells that 
have   suffered   irreversible injury with damage/leakage in 
plasma   membrane). A comparable percentage of early/late 
apoptotic and dead cells was observed between NIR815-
labeled and unlabeled hMSCs (CTR) indicating that the 
dye had no effect on cell viability (Figure 2A).
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
439
Live imaging of hMSCs transplanted in parkinsonian ratsInternational Journal of Nanomedicine 2012:7
We also determined the cell proliferation and cell 
  survival capacity of NIR815 hMSCs compared with CTR. 
The proliferation curve of  NIR815 hMSCs was analogous to 
that obtained with CTR (Figure 2B). Both cell populations 
could be maintained in culture over several passages (up to 
seven passages, 42 days in vitro) without significant changes 
in duplication. Similarly, survival of NIR815 hMSCs was 
comparable with that observed for CTR at each time point 
considered (Figure 2C).
Important issues were to determine how the NIR815 signal 
diminished in tagged hMSCs over time as a consequence of 
cell division, and to evaluate the number of labeled cells that 
may be detected in vitro as a function of time. Serial dilutions 
of NIR815 hMSCs were seeded on coverglasses at one, 14, 
Figure 2 Effect of NIR815 dye on human mesenchymal stem cells. (A) Flow cytometry analysis of unlabeled and NIR815 human mesenchymal stem cells, 0 and 20 hours 
after staining procedures. (B) Cell proliferation, cumulative number of human mesenchymal stem cells at different days in vitro following labeling with NIR815 dye. (C) Cell 
survival, with cell viability examined by MTS assay at different time points as indicated below the graph.
Note: Data are presented as the mean ± standard deviation from three replicates of three different experiments.
Abbreviations: OD, optical density; PI, propidium iodide; hMSCs, human mesenchymal stem cells; DIV, days in vitro.
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and 28 days in vitro after labeling, and near-infrared signal 
intensities (800 nm channel) were determined. Our data show 
that a quantifiable near-infrared signal was detectable at all 
time points considered and cell dilutions evaluated (Figure 3A). 
A significant and quantitative signal was detected and well pre-
served for up to 28 days in vitro, notwithstanding cell division. 
Relative signal intensities were also preserved between serial 
cell concentrations along passages (Figure 3A and B).
We also assessed whether some dye transfer could be 
detected in vitro. Our data show that while some leakage was 
observed for Hoechst, this phenomenon was not detected fol-
lowing NIR815 labeling (Figure 4). CD90, a surface marker 
expressed on hMSCs, was used to confirm the presence and 
human nature of the cells. Unlabeled hMSCs incubated with 
supernatants from double-labeled hMSCs (CM24 and CM72) 
showed a weak Hoechst signal, clearly distinguishable from 
that observed in positive CTR (Figure 4A). Conversely, no 
NIR815 staining could be detected in cells incubated with 
CM72, clearly indicating that the NIR815 dye did not leak 
from tagged cells (Figure 4B).
In vivo tracking of NIR815 hMSCs  
in parkinsonian rats
Animals received a unilateral injection of 6-OHDA in the 
right striatum. This toxin induces an immediate loss of 
dopaminergic terminals in the striatum that progresses and 
stabilizes over a 2-week period. Tagged hMSCs were infused 
5 days after 6-OHDA injection when the toxin-induced neu-
rodegenerative process was still ongoing.7,8
Intrastriatal delivery of tagged hMSCs
Near-infrared scans of the animal’s head were performed 
immediately before the 6-OHDA-induced lesion and 5 days 
later just before the transplantation procedure (see Material 
and Methods section and Figure 1A). Near-infrared scans 
were then performed at different time points after intrastriatal 
transplantation of NIR815 hMSCs (Figures 1A, 5A and B). 
No near-infrared background signal linked to the surgical pro-
cedures per se was observed. An intense near-infrared signal 
was detected at T1 and T14 after grafting; a reduction in the in 
vivo signal intensity was observed over time (Figure 5B).
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Figure 3 Preservation of NIR815 tag over time. Cells were labeled using the CellVue® NIR815 kit and maintained in culture. NIR815 signal intensity was determined at 
various time points (1, 14, and 28 days in vitro) in serial cell dilutions (80 × 103, 40 × 103, 20 × 103, 10 × 103, 5 × 103, and 2 × 103 near-infrared human mesenchymal stem 
cells). (A) Signal intensity detected at 1, 14, and 28 days in vitro as indicated above the graphs. Numbers below the x axis indicate the number of NIR815 human mesenchymal 
stem cells. (B) Signal intensity detected for 80 × 103, 20 × 103, and 5 × 103 NIR815 human mesenchymal stem cells. Numbers below the x axis indicate the days in vitro at 
which scan was performed. The near-infrared signal is expressed as arbitrary units.
Note: Data are presented as the mean ± standard deviation from three replicates of three different experiments.
Abbreviations: DIV, days in vitro; hMSCs, human mesenchymal stem cells.
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CTR+ CM24 CM72
Hoechst
Merge
B
Figure 4 Dye transfer. Cells were double-labeled with hoechst and CellVue® NIR815, their conditioned media taken up at various time points (24 and 72 hours) and used 
to assess possible leakage of either dyes. (A) Detection of hoechst staining (blue) in CD90-positive hMSCs (red). CTR+: human mesenchymal stem cells directly labeled with 
the NIR815 dye (positive control); CM72: CD90 human mesenchymal stem cells incubated with conditioned media obtained 72 hours after NIR815 labeling. Scale bar 10 µm. 
(B) Detection of NIR185 signal in CD90-positive human mesenchymal stem cells. CD90 signal is shown in red, CellVue signal is shown in green.
Abbreviations: CTR-, CD90-positive human mesenchymal stem cells in the absence of NIR815 staining; CTR+, CD90 human mesenchymal stem cells directly labeled 
with the NIR815 dye; CM24, CD90 human mesenchymal stem cells incubated with conditioned media obtained 24 hours after near-infrared labeling; CM72, CD90 human 
mesenchymal stem cells incubated with conditioned media obtained 72 hours after NIR815 labeling.
To confirm the exogenous origin of the near-infrared 
signal, animals were sacrificed at T14 (Figure 1A) and whole 
brains were immediately scanned to detect and localize the 
specific labeling (Figure 5C, green arrow). Serial coronal 
brain sections containing the striatum were then obtained and 
directly analyzed using the near-infrared scanner. A specific 
intense green near-infrared signal corresponding to the tagged 
hMSCs was detected in situ (Figure 5D1). High intensity 
scanning in the NIR700 channel allowed detection of a non-
specific red signal due to the tissue and permitted regional 
localization of the transplanted cells within the striatum.
Tyrosine hydroxylase immunohistochemistry using a 
specific secondary antibody emitting in the NIR700 spectrum 
allowed simultaneous localization of the transplanted NIR815 
hMSCs (Figure 5D2, green) and tyrosine hydroxylase-positive 
dopaminergic terminals (Figure 5D2, red). The lack of tyrosine 
hydroxylase staining in the right striatum clearly indicates the 
6-OHDA-induced lesion (Figure 5D2, dotted white circle). 
Fluorescent microscopy subsequently allowed detection of 
Hoechst-labeled/CD90-positive hMSCs perfectly matching 
to the near-infrared signal (Figure 5D3). Three-dimensional 
reconstruction using Neurolucida further demonstrated striatal 
localization of the transplanted cells (Figure 6).
Intranasal delivery of tagged hMSCs
In vivo tracking of NIR815 hMSCs following intranasal 
injection in parkinsonian animals allowed immediate and 
time-dependent localization of the cells. Anesthetized animals 
received an intranasal administration of NIR815 hMSCs in the 
right nostril and were scanned every 10 minutes (see   Materials 
and Methods section). Cells were clearly visible in the 
  nostril close to the olfactory epithelium at the first time point 
(10 minutes, see Figures 1B and 7A). The signal progressively 
moved towards the orifice of the nostril and diminished 
  significantly over a 30-minute period (compare Figure 7A 
and B). No NIR815 hMSCs were detectable 60 minutes after 
intranasal injection (Figure 7B). Accordingly, no Hoechst 
signal was detected in brain coronal slices (not shown).
Discussion
We have previously shown that transplantation of Hoechst-
labeled hMSCs in the striatum of rats bearing a 6-OHDA 
lesion counteracted progressive toxin-induced nigrostriatal 
neurodegeneration and associated behavioral alterations,9 and 
enhanced endogenous neurogenesis.10 In the present study, 
we used this well characterized experimental paradigm to 
validate an in vivo imaging procedure to track stem cells 
using a near-infrared platform. To the best of our knowledge, 
this is the first study that addresses the use of near-infrared 
technology to track the fate, in living parkinsonian animals, 
of near-infrared-labeled cells following two different admin-
istration routes, ie, intrastriatal and intranasal.
Near-infrared fluorescence allows in vivo visualization 
of molecular targets both at the microscopic and whole 
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animal macroscopic levels in relation to the chosen probe 
properties.20,21 The peculiar characteristics of near-infrared 
technology have been already translated into a clinical 
medical imaging device for image-guided surgery using 
exogenous contrast agents.22,23 The use of near-infrared 
light imaging has also been recently proposed to ameliorate 
the correct delivery of genes to target tissues and monitor 
therapeutic efficacy in gene therapy.24 Staining cells with 
the NIR815 tracer is simple and can be performed rapidly 
using short incubation procedures that can be applied to 
any cell without the requirement of tedious transfection or 
potentially dangerous transduction protocols. Near-infrared 
dye represents an important advantage compared with other 
procedures that use retroviruses or lentiviruses and that 
are not directly applicable to patients. To exclude concerns 
regarding near-infrared cytotoxicity,25 we first determined 
whether the NIR815 dye interfered in any way with normal 
stem cell metabolism and proliferation/survival. Our exten-
sive in vitro data demonstrate that near-infrared labeling has 
no toxic effect on cells; the slight increase in early apoptosis 
observed in NIR815 hMSCs compared with unlabeled cells 
may be considered physiological. A clear limitation of the 
staining procedure might be the dilution of the near-infrared 
signal due to active cell proliferation. However, our results 
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Figure 5 In vivo and ex vivo detection of NIR815 human mesenchymal stem cells following intrastriatal injection. (A) Animals were anesthetized and head imaging was 
performed immediately before intrastriatal injection of 6-hydroxydopamine (CTR), 1 and 14 days after intrastriatal injection of NIR815 human mesenchymal stem cells. Scans 
were performed at 800 nm with laser intensity set at 7, a resolution of 84 µm, and focus at 4 mm. Arrows within the dotted area (shaved area) indicate the transplanted 
cells visualized in green at 800 nm (NIR815, white arrow) or in pseudocolors (red arrows). Pseudocolors correlate with signal intensity (arbitrary units) as indicated. Signals 
(green and pseudocolors) observed outside of the dotted area represent background due to the animal’s fur. (B) Signal intensity in 6-hydroxydopamine animals 1 and 
14 days after transplantation. (C) At the time of sacrifice, whole brains were removed and scanned immediately; near-infrared channel 700 scan intensity 7; near-infrared 
channel 800 scan intensity 3; resolution 84 µm; and focus offset 4 mm. NIR815 human mesenchymal stem cells are clearly detectable (green arrow). The red signal represents 
nonspecific tissue autofluorescence at 700 nm. (D) Sequential ex vivo detection of NIR815 human mesenchymal stem cells following intrastriatal transplantation on coronal 
brain sections. (D1) Coronal brain sections were picked up on poly-lysine slides and high-throughput low-resolution scan was performed immediately (near-infrared channel 
700 scan intensity 7, near-infrared channel 800 scan intensity 3, resolution 169 µm, and focus 1 mm). Localization of the transplanted NIR815 human mesenchymal stem cells 
is clearly visible. The red signal represents nonspecific tissue autofluorescence at 700 nm. (D2) Serial coronal sections were stained using a primary antityrosine hydroxylase 
antibody and revealed using a NIR700 secondary antibody. Sections were dried and high-resolution scans were performed on single slides at a time (NIR700 scan intensity 3, 
NIR800 scan intensity 3, resolution 21 µm, and focus offset 1 mm). The 6-hydroxydopamine-induced lesion is indicated by the absence of striatal tyrosine hydroxylase staining 
in the right hemisphere (dotted circle). Transplanted cells within the lesioned area are clearly visible. (D3) The same serial coronal sections used in D2 were stained using a 
primary anti-CD90 antibody and revealed using an AlexFluor594 secondary antibody. Sections were mounted and microscopic detection of hoechst/CD90-positive human 
mesenchymal stem cells was performed as a proof-of-principle of near-infrared evaluation. hoechst/CD90 labeled cells that colocalized with near-infrared staining as shown 
in the squared box in D2 demonstrate the specificity of the detected signals..
Notes: Data represent the mean ± standard deviation. *P , 0.01 versus CTR, analysis of variance; Scale bar 10 µm.
Abbreviations: NIR, near-infrared; hMSCs, human mesenchymal stem cells.
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show that a close correlation between signal intensity and 
cell number was preserved, even after an extended period 
of time. The ratio for cell dilution to near-infrared intensity 
diminished with time, but was proportionally maintained both 
in vitro and in vivo. We have previously shown that hMSCs 
do not proliferate following intracerebral transplantation in 
rats with Parkinson’s disease,9 thus limiting the possibility 
of loss-of-signal over time in vivo.
Possible leakage of Hoechst 33342 dye into host cells 
has been reported previously.26 To minimize this problem, 
we used a different Hoechst compound (33258) that showed 
reduced passage from cell to cell in vitro. Importantly, our 
data clearly show that NIR815 dye was not released from 
labeled hMSCs even after several days in culture, and further 
support the use of intercalating near-infrared dyes to label 
cells for in vivo tracking. Our results also demonstrated that 
hMSCs can be efficiently tagged using intercalating NIR815 
dye without effects on cell viability and proliferation.
We directly transplanted NIR815 hMSCs into the striatum 
of 6-OHDA-lesioned rats. In this well characterized rodent 
model of Parkinson’s disease,7,8 the toxin induces progressive 
retrograde neurodegeneration of the nigrostriatal pathway. 
In our experimental paradigm, cells are transplanted in 
the ipsilateral striatum 5 days after toxin injection, when 
neurodegenerative processes are still ongoing. The extent 
of progressive neurodegeneration resembles the inimical 
conditions that stem cell therapy would face in patients with 
Parkinson’s disease. In this study, we show that transplanted 
NIR815 hMSCs could be promptly tracked in vivo over an 
extended period of time in 6-OHDA lesioned rats. In vivo 
near-infrared imaging connected to a computer analysis 
system allowed longitudinal semiquantitative evaluation of 
cell survival in a selected cohort of transplanted animals. 
Therefore, near-infrared technology considerably reduced 
both the number of animals necessary for a given experimen-
tal setting and avoided the demanding firsthand sectioning 
of whole brain to perform analyses at each experimental 
time point. Importantly, near-infrared signal from the cells 
was easily detected through the scalp and skull at a depth 
of at least 5 mm.
Findings from in vivo near-infrared imaging after intras-
triatal delivery were confirmed by ex vivo analyses of whole 
Section
+
NIR scan
3D reconstruction
(Neurolucida)
Transparent
striatum
90° rotation
180° rotation
NIR-hMSCs
Striatum
Cortex
90° rotation
Contour
(Neurolucida)
Cortex
striatum NIR-hSMCs
Figure 6 Three-dimensional reconstruction. Coronal sections were scanned and images imported into the Neurolucida software; contour of whole brain, striata, and 
transplanted cells was performed and partial three-dimensional images of NIR815 human mesenchymal stem cells within the lesioned striatum were obtained.
Abbreviations: NIR, near-infrared; hMSCs, human mesenchymal stem cells; 3D, three-dimensional.
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brain and coronal brain sections. Selected brain sections were 
directly scanned, operating the same near-infrared platform 
previously used for in vivo evaluation. Precise   intracerebral 
localization of the transplanted cells was assessed immediately. 
Distribution of grafted near-infrared hMSCs could be   localized 
ex vivo in tissue sections with high throughput by scanning 
many slides at once. Near-infrared imaging indicated that 
exogenous cells mostly remained within the site of injection 
and did not migrate towards other brain areas. These data 
were further confirmed by fluorescent microscopy showing 
that Hoechst-positive hMSCs were distributed in the striata 
of animals within the boundaries of the 6-OHDA-induced 
lesion. Imaging of near-infrared-labeled hMSCs could be 
combined with staining of selected proteins, such as tyrosine 
hydroxylase, using near-infrared secondary antibodies, thus 
allowing direct visualization of transplanted cells within the 
lesioned striatum, characterized by reduced tyrosine hydroxy-
lase staining. Similar results have been obtained in a rat model 
of permanent middle cerebral artery occlusion.27 Furthermore, 
the clear colocalization of the CD90 antigen, a marker of naïve 
hMSCs, and either Hoechst 33258 and/or NIR815, in vitro 
and ex vivo further confirmed the specific human nature of 
the transplanted cells we observed.
Intracerebral transplantation is an invasive route of 
administration and its use in humans remains limited for 
safety reasons, as well as because of the high costs linked 
to the procedure. Direct intranasal delivery of therapeutics 
from the nasal cavity into the central nervous system rap-
idly bypasses the blood–brain barrier, reducing systemic 
exposure and side effects, and provides an alternative route 
to invasive intracerebral methods of drug/cell administra-
tion.28,29 Intranasal delivery of target drugs to the central 
nervous system has already shown many benefits in the 
treatment of neurologic disorders.28 However, to date, few 
studies have addressed the feasibility and safety of this route 
of cell administration.18 In our study, we showed that tagged 
NIR815 hMSCs could be detected immediately following 
infusion by either the intranasal or intrastriatal route. NIR815 
hMSCs injected via the intrastriatal route were detectable 
in vivo for up to 14 days. Conversely, no near-infrared 
signal was measurable 60 minutes after intranasal injec-
tion, suggesting that labeled hMSCs were rapidly expelled 
from the nasal cavity. We could not a priori exclude that a 
small percentage of cells, below the detection capacity of 
our near-infrared platform, had passed across the olfactory 
epithelium and reached the central nervous system. A sub-
sequent thorough ex vivo analysis of brain sagittal sections, 
including the olfactory bulb, further confirmed the absence 
of labeled hMSCs (NIR815 or Hoechst), corroborating our 
live in vivo observations.
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Figure 7 In vivo tracking of NIR815 human mesenchymal stem cells following intranasal injection. (A) Animals were anesthetized and head imaging was performed 
immediately after intranasal injection of NIR815 human mesenchymal stem cells. Scans were performed at 800 nm with laser intensity set at 7, resolution of 169 µm, and 
focus offset at 4 mm. Arrows within the dotted area (shaved area) indicate the transplanted cells visualized in green at 800 nm (white arrows) or in pseudocolors (red arrows) 
which clearly correlate with signal intensity (arbitrary units) as indicated. (B) Decrease of near-infrared labeling in 6-hydroxydopamine animals at various time points after 
intranasal injection.
Notes: Data represent the mean ± standard deviation. *P , 0.01 versus CTR, analysis of variance.
Abbreviations: NIR, near-infrared; mn, minutes.
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Our findings show that near-infrared technology allows 
follow-up of grafted stem cells both immediately and over 
time, and support the use of near-infrared imaging as a 
valuable method to track stem cell engraftment/homing 
processes after transplantation.30 In the future, near-infrared 
technology will permit more rapid and efficient development 
of the correct experimental conditions necessary to obtain 
optimal cell transfer from nose to brain without the require-
ment of a large number of animals and time consuming 
post-experimental procedures, including brain sectioning 
and immunohistochemical staining.
Conclusion
Exploiting near-infrared imaging for in vivo tracking of trans-
planted tagged cells holds enormous potential for neurobiologi-
cal research. This technology can be readily accessible in any 
laboratory without the requirement for expensive clinical diag-
nostic equipment and specialized technical abilities, compared 
with those required for other in vivo imaging technologies 
(ie, magnetic resonance). This technique allows conducting 
analyses from whole animals to the single cell. Importantly, 
near-infrared labeling avoids complicated transduction pro-
cedure using viruses and offers important opportunities to 
develop this noninvasive imaging procedure readily applicable 
to patients. Such technology will help validate novel cellular 
transplantation strategies for the treatment of neurodegenera-
tive diseases, including Parkinson’s disease.
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